Intravitreal Bevacizumab (Avatin) for Neovacular Age-related Macular Degeneration: A hort-term tudy

Purpoe To report the hort-term tudy of intravitreal bevacizumab (Avatin) in the treatment of neovacular age-related macular degeneration (AMD). Deign Interventional, conecutive, propective cae erie. Method One hundred and two eye of 102 patient with neovacular AMD received monthly intravitreal bevacizumab (Avatin) (1.25 mg) until reolution of macular edema, ubretinal fluid, and/or pigment epithelial detachment. Outcome meaure included viual acuity (VA) and central retinal thickne a defined from optical coherence tomography (OCT). Reult Mean VA wa 20/80 and OCT central retinal thickne wa 251.0 ± 74.6 μm before injection and improved to 20/63 and 214.9 ± 41.7 μm at ix week (P < .001), 20/50 and 204.8 ± 33.6 μm at 10 week (P < .001), and remained table at 20/50 and 210 μm after 14 week (P < .05). No ignificant ocular or ytemic ide effect were oberved. Concluion Intravitreal bevacizumab (Avatin) appear to be beneficial and well tolerated in the treatment of neovacular AMD in the hort term. Further comparative evaluation againt other antivacular endothelial growth factor (VEGF) agent and doing chedule i warranted.